QLC5508 combined with other cancer drugs for advanced solid tumors
A Phase Ib/II, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of QLC5508 in Combination With Other Anti-tumor Agents in Patients With Advanced Solid Tumors
This will test QLC5508 given with other cancer medicines to see if it is safe and helps adults with advanced solid tumors.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 444 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Qilu Pharmaceutical Co., Ltd. Industry-sponsored |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT07256782 on ClinicalTrials.gov |
What this trial studies
This phase Ib/II, open-label, multi-center study in China uses a dose-escalation followed by dose-expansion design to study QLC5508 in combination with other anti-cancer agents. The dose-escalation phase enrolls patients who have progressed on or are intolerant to standard therapies to identify safe and tolerable dose levels, and the dose-expansion phase enrolls patients who have not received prior treatment for advanced/metastatic disease. Key outcomes include safety, tolerability, pharmacokinetics, and anti-tumor activity measured by RECIST v1.1. Combinations being tested include QL1706, QL2107, paclitaxel, and platinum chemotherapy (cisplatin or carboplatin).
Who should consider this trial
Good fit: Adults (≥18) with histologically or cytologically confirmed advanced solid tumors, ECOG 0–1, measurable disease, and either progressed on or intolerant of standard therapies (dose-escalation) or untreated for advanced/metastatic disease (dose-expansion).
Not a fit: Patients who previously received B7‑H3–targeted therapy, who have poor performance status or life expectancy under 12 weeks, or who are pregnant are unlikely to benefit or are ineligible.
Why it matters
Potential benefit: If successful, these combinations could provide a new targeted treatment option that shrinks tumors or prolongs disease control for people with advanced solid tumors.
How similar studies have performed: Other early-phase trials of B7‑H3–targeting antibody–drug conjugates have shown preliminary signs of activity but remain investigational and not yet proven in larger studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * At least 18 years of age at screening; * Histologically or cytologically confirmed advanced solid tumors: Dose escalation part will enroll participants who have progressed on or are intolerant to available standard therapies. Dose expansion part will enroll participants who have not received prior treatment for advanced/metastatic diseases. * At least one measurable target lesion according to RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1 * Life expectancy ≥12 weeks * Female or male participants should be willing to use appropriate contraceptive measures throughout the study; * Female participants should have a negative blood pregnancy test within 7 days prior to the first dose or have evidence of non-childbearing potential; * A signed written Informed Consent Form Exclusion Criteria: * . Received or undergoing any of the following treatment: 1. Previous or current treatment with B7-H3 targeted therapy 2. Previous or current treatment with topoisomerase I inhibitors 3. Previous treatment with cytotoxic chemotherapy, investigational agents, traditional Chinese medicine with an anti-tumor indication and antitumor drugs within 14 days prior to the first dose 4. Previous treatment with macromolecular antitumor drugs within 28 days prior to the first dose f. Radiotherapy with a limited field of radiation within 2 weeks prior to the first dose; or more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first dose e. Pleural effusion or ascites requiring clinical intervention; or presence of pericardial effusion f. Major surgery within 4 weeks prior to the first dose g. Brain metastases; leptomeningeal or brainstem metastases; or spinal cord compression * Unresolved AEs ≥ Grade 2 (CTCAE v5.0) from prior therapy except for alopecia and residual neuropathy * Previous or concurrent primary malignancies * Inadequate bone marrow reserve or organ dysfunction * Evidence of cardiovascular risk * Evidence of current severe or uncontrolled systemic diseases * Severe infection within 4 weeks prior to the first dose; or uncontrolled active infection at screening * Known or suspected interstitial lung disease; or other moderate to severe pulmonary diseases that significantly impair respiratory function and may interfere with the detection or management of drug-related pulmonary toxicity * High risk of gastrointestinal or abdominal bleeding 10. Gastrointestinal diseases of clinical significance within 3 months prior to the first dose * History of severe neuropathy or mental disorders * History of severe hypersensitivity reaction, severe infusion reaction or idiosyncrasy to drugs chemically related to QLC5508 or any of the components of QLC5508 * Unlikely to comply with study procedures and requirements in the opinion of the investigator * Any disease or condition that, in the opinion of the investigator, would compromise participant safety or interfere with study assessments
Where this trial is running
Shanghai
- Shanghai East Hospital — Shanghai, China (Recruiting)
Study contacts
- Study coordinator: Qianyun Liu, Master
- Email: qianyun.liu@qilu-pharma.com
- Phone: +8653155821177
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.